AVM Biotechnology
Seattle, US · Washington LLC
AVM Biotechnology develops AVM0703, a proprietary concentrated dexamethasone formulation designed to trigger the release and production of specialized immune cells (gamma delta and invariant TCR+ bispecific T lymphocytes and NK T-like cells) as a treatment approach for various diseases. The company operates in the biotechnology and immunotherapy space, with a therapeutic candidate in pre-clinical and clinical stages.
Founders & leadership
TD
Theresa DeisherCEO, Manager
Reported raises · per SEC filings
Form D private placements$12.8M disclosed across 4 rounds · 2014–2021
▶$4.4MraisedMay 2021 · 22 investors · BiotechnologyRule 506(b)
▶$4.4MraisedMay 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Theresa DeisherExecutive Officer, Director
- Offering amount
- $14.7M
- Amount sold
- $4.4M
- Minimum investment
- $25K
- Sales commissions
- $35K
- Placement agents
- Todd Colin Bertsch
- First sale
- Apr 2021
- Incorporated
- Limited Liability Company, Washington
- Federal exemptions
- 06b
▶$1.4MraisedMay 2019 · 13 investors · BiotechnologyRule 506(b)
▶$1.4MraisedMay 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Theresa DeisherExecutive Officer, Director
- Offering amount
- $14.7M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- First sale
- Apr 2019
- Incorporated
- Limited Liability Company, Washington
- Federal exemptions
- 06b
▶$5.5MraisedDec 2017 · 25 investors · BiotechnologyRule 506(b)
▶$5.5MraisedDec 2017 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Theresa DeisherDirector
- Offering amount
- $17.5M
- Amount sold
- $5.5M
- Minimum investment
- $100K
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Washington
- Federal exemptions
- 06b
▶$1.5MraisedApr 2014 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedApr 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Theresa DeisherExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.5M
- Minimum investment
- $50K
- Proceeds to insiders
- $150K
- First sale
- Apr 2014
- Incorporated
- Limited Liability Company, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Adaptive Biotechnologies9 shared keywordsAdaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies. Its Immune Medicine Platform is used to detect, monitor, and treat disease.
Aro Biotherapeutics9 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Agenus7 shared keywords
Companies competing with AVM Biotechnology for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $399.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $211K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does AVM Biotechnology do?
- AVM Biotechnology develops AVM0703, a proprietary concentrated dexamethasone formulation designed to trigger the release and production of specialized immune cells (gamma delta and invariant TCR+ bispecific T lymphocytes and NK T-like cells) as a treatment approach for various diseases. The company operates in the biotechnology and immunotherapy space, with a therapeutic candidate in pre-clinical and clinical stages.
- Who founded AVM Biotechnology?
- AVM Biotechnology was founded by Theresa Deisher.
- How much funding has AVM Biotechnology raised?
- AVM Biotechnology has disclosed $12.8M raised across 4 rounds.
- Where is AVM Biotechnology headquartered?
- AVM Biotechnology is headquartered in Seattle, US.